IBD: Indication extrapolation for anti-TNF biosimilars

Nature Reviews Gastroenterology and Hepatology

Volumn 12, Issue 7, 2015, Pages 373-374

  Vande Casteele, Niels ^a   Sandborn, William J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CT P13; TUMOR NECROSIS FACTOR ANTIBODY; UNCLASSIFIED DRUG; BIOSIMILAR AGENT; BISPECIFIC ANTIBODY; CT-P13; TUMOR NECROSIS FACTOR;

ANKYLOSING SPONDYLITIS; ANTIBODY TITER; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG APPROVAL; DRUG CROSS REACTIVITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDICATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; HUMAN; IMMUNOGENICITY; IMMUNOREGULATION; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SHORT SURVEY; THERAPEUTIC EQUIVALENCE; ULCERATIVE COLITIS; COLITIS, ULCERATIVE; DRUG EFFECTS; SYNTHESIS;

ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; BIOSIMILAR PHARMACEUTICALS; COLITIS, ULCERATIVE; CROHN DISEASE; HUMANS; INFLIXIMAB; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84934857007     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2015.104     Document Type: Short Survey

References (10)

1. Park, W. et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann. Rheum. Dis. 72, 1605-1612 (2013).
2. Yoo, D. H. et al. A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study. Ann. Rheum. Dis. 72, 1613-1620 (2013).
3. Ben-Horin, S. et al. Cross-immunogenicity: antibodies to infliximab in Remicade-treated patients with IBD similarly recognise the biosimilar Remsima. Gut http://dx.doi.org/10.1136/gutjnl-2015-309290.
4. Ravetch, J. V., Bolland, S. IgG Fc receptors. Ann. Rev. Immunol. 19, 275-290 (2001).
5. Feagan, B. G. et al. The challenge of indication extrapolation for infliximab biosimilars. Biologicals 42, 177-183 (2014).
6. Shen, C. et al. Adalimumab induces apoptosis of human monocytes: a comparative study with infliximab and etanercept. Aliment. Pharmacol. Ther. 21, 251-258 (2005).
7. Van den Brande, J. M. et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774-1785 (2003).
8. Xu, Z. et al. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J. Clin. Pharmacol. 48, 681-695 (2008).
9. Fasanmade, A. A. et al. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur. J. Clin. Pharmacol. 65, 1211-1228 (2009).
10. Kuo, T. T. et al. Neonatal Fc receptor: from immunity to therapeutics. J. Clin. Immunol. 30, 777-789 (2010).